Shares of Roivant Sciences Ltd. (ROIV) are climbing about 17 percent on Friday morning trading over the announcement of positive results from the Phase 2 study of brepocitinib in cutaneous sarcoidosis.
Currently, ROIV is trading at $24.92, up 17.88 percent, over the previous close of 21.14 on the Nasdaq. The stock opened at $23.97 and has climbed as high as $25.49 so far in today's session. Over the past year, it has traded in a range of $8.73 to $25.49.
In the study, brepocitinib significantly improved disease activity, achieving a 22.3-point improvement in mean Cutaneous Sarcoidosis Activity and Morphology Instrument - Activity (CSAMI-A) score at Week 16, compared with a 0.7-point improvement with placebo. The treatment showed rapid and sustained improvements across other efficacy measures with a consistent safety profile.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.